[Do diabetic patients benefit from bilateral internal mammary artery?]
Bilateral internal mammary artery (BIMA) grafting has been associated with increased long term survival when compared to single IMA, but its benefit on diabetic patients remains controversial. To compare long-term survival following BIMA versus single internal mammary artery (SIMA) grafting between diabetic and non-diabetic patients. We retrospectively reviewed all the patients who underwent isolated CABG and received two or more grafts with at least one IMA graft between 2004 and 2013. Mean follow-up was 4 years and maximum 10. Kaplan-Meier analysis was used to compare long-term survival between BIMA and SIMA in both groups (diabetic vs. non-diabetic). Propensity score matching was used to adjust for treatment selection bias. 1259 out of 3045 eligible patients were diabetic. BIMA was associated with better long-term survival than SIMA on unadjusted analysis in both groups (cumulative survival of 87% vs. 70% in diabetic patients and 89% vs. 79% in non-diabetic patients, respectively). After propensity score matching, BIMA was associated with increased long-term survival in the non-diabetic cohort (n=1042, HR: 0.570 CI95%: 0.342-0.950), but there was no statistically significant difference in the diabetic cohort (n=850, HR: 0.774 CI95% 0.447-1.339). In-hospital mortality and sternal wound infection were low in matching cohorts irrespectively of the number of IMA grafts or diabetes status. BIMA grafting appears to be safe for diabetic patients, despite the apparent lack of significant survival advantage.